Characteristics and outcomes of patients with metastatic KRAS mutant lung adenocarcinomas: The Lung Cancer Mutation Consortium experience.

Badi El Osta,Madhusmita Behera,Sungjin Kim,Lynne D Berry,Gabriel Sica,Rathi N Pillai,Taofeek K Owonikoko,Mark G Kris,Bruce E Johnson,David J Kwiatkowski,Lynette M Sholl,Dara L Aisner,Paul A Bunn,Fadlo R Khuri,Suresh S Ramalingam

Journal of Thoracic Oncology（2019）

引用 142|浏览46

暂无评分

摘要

In the LCMC study, 27% of lung adenocarcinomas patients harbored a KRAS mutation and up to third of them had another oncogenic driver. Patients with both KRAS and STK11 mutations had a significantly inferior clinical outcome.

查看译文

关键词

KRAS mutation,STK11 mutation,LKB1 mutation,Lung adenocarcinomas,Lung Cancer Molecular Consortium,Precision oncology

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要